Corbus Q3 net loss $10.1M; pipeline progress with CRB-701, CRB-601, CRB-913

Corbus Pharmaceuticals Holdings, Inc.

2023-Q3 EPS reported -$8.52

Net loss of $10.1M ($2.27 per diluted share) vs $8.8M ($2.11) in Q3 2022.
Cash, equivalents, and investments of $28.7M as of Sept 30, 2023.
CRB-701 Phase 1 dose escalation ongoing; early clinical data expected Q1 2024 alongside U.S./EU trial start.
IND submission for CRB-601 on track for Q4 2023; pre-clinical data presented at SITC.
CRB-913 pre-clinical study published in Obesity; shows no lean muscle loss when combined with incretins.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Corbus Pharmaceuticals Holdings, Inc. reported financial results for the third quarter of 2023.

Period: the third quarter of 2023
Result: reported results

Exact text from the filing

today provided a corporate update and reported financial results for the third quarter of 2023.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

Corbus Pharmaceuticals Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-059812

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.